Committed to the Future of Antibiotics

16 June - 20 June 2016

Da Volterra at ASM Microbe 2016

We are happy to announce our participation at ASM Microbe on (...)

6 June - 9 June 2016

Da Volterra will attend the 2016 BIO International Convention June 6-9 in San Francisco, California

The Da Volterra team is excited to participate in the 2016 BIO (...)

9 May 2016

Da Volterra Acknowledges and Supports the French Initiative against Antimicrobial Resistance

The French Minister for Health, Mrs. Marisol Touraine, has just (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >


Developpeur PHP Drupal